Edelmann establishes Edelmann Leaflet Solutions

Published: 10-Oct-2011
Packaging Finance

New firm is a merger of two of its operations in Germany

The Edelmann Group, a German folding cartons and leaflet specialist, is bundling its activities in the leaflets business into a new company called Edelmann Leaflet Solutions.

The newly founded company will merge two of the Group’s operations in Germany – Lindauer Druckerei Eschbaumer in Lindau and Wepack in Leverkusen.

The Heidenheim-based Edelmann Group extended its leaflets business in June by installing up-to-date folding machines in its facilities and with an overall annual capacity of 1.5 billion units, it is now one Germany’s largest leaflet manufacturers.

The firm says establishing Edelmann Leaflet Solutions will allow orders to be managed outside the individual facilities in Lindau and Leverkusen. This means that capacities can be increased at short notice and the duration of projects shortened while increasing flexibility.

In total Edelmann operates 12 sites serving the healthcare and beauty sectors: in Germany (Carl Edelmann, Artur Theis, Braun Pharmadruck, Lindauer Druckerei Eschbaumer, Wesche and Wepack), France (Edelmann France), Poland (Edelmann Poland), Hungary (Zalai Nyomda), Mexico (Edelmann Mexico) and China (Edelmann Beijing) and employs around 1,500 people.

In 2010, the Group generated revenue of €188m. Worldwide it produced 4.2 billion items of folding cartons and leaflets.

See more

You may also like

Packaging

The future of the package insert: the on-pack booklet-label

Read more
Novel solution developed by Schreiner MediPharm and Edelmann

Trending Articles

  1. Strengthening US pharmaceutical supply: SCHOTT Pharma inaugurates expanded vial production in Lebanon, PA SCHOTT Pharma has inaugurated new production lines for both standard and sterile ready-to-use (RTU) glass vials designed to store a wide range of drugs — from biologics and other complex injectable therapies to vaccines and emergency room medications
  2. T-CURX acquires Pantherna Therapeutics to fast-track non-viral in vivo CAR-T pipeline Combining transposon-based CAR-T with Pantherna's LNP and mRNA platforms, T-CURX aims to accelerate clinical trials by a year and become Europe's first biotech with both technologies in-house
  3. Eli Lilly to expand into infectious disease with $4bn triple vaccine acquisition The pharma giant has reportedly agreed to acquire Curevo, LimmaTech Biologics and Vaccine Co in a strategic push beyond its blockbuster obesity franchise
  4. Next expansion milestone achieved: SCHOTT Pharma opens production facility in Serbia to strengthen competitiveness in Europe After a double-digit million euro investment and less than 1.5 years of construction, SCHOTT Pharma opens new manufacturing site in Jagodina, Serbia. Production capacity to meet European market demand for pharmaceutical ampoules. Facility brings around 180 new jobs to the region
  5. Almac group delivers record year of growth Revenue rises to £1.1 billion as profit increases 16% and workforce expands to more than 7,900 amid continued global investment programme

Upcoming event

BIO International Convention

22–25 June 2026 | Convention | Boston, US See all

You may also like

Packaging

The future of the package insert: the on-pack booklet-label

Novel solution developed by Schreiner MediPharm and Edelmann
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

Packaging firms develop smarter options

While serialisation is top of most agendas, the development of Cloud-based services and smart phone solutions also offer new marketing opportunities. Susan Birks reports
Packaging

Edelmann wins Pharmapack Award for vial packaging

Third award won by folding carton concept
Packaging

Edelmann leads development of standard for tamper-evident closures

European working group will publish initial draft this year
Packaging

Edelmann increases label production capacity

Invests in folding machines at three plants
Manufacturing

AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn

AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Finance

GSK acquires Nuvalent for $10.6bn to accelerate NSCLC pipeline with FDA-reviewed ROS1 and ALK inhibitors

GSK has agreed to acquire clinical-stage oncology company Nuvalent for $10.6bn, securing two late-stage next-generation kinase inhibitors — zidesamtinib and neladalkib — currently under FDA review for potential 2026 approval in non-small cell lung cancer
Subscribe now